JAZZ
Jazz Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About JAZZ
Jazz Pharmaceuticals Public Limited Company
A company that developing drugs in the therapeutic areas of narcolepsy, oncology, pain, and psychiatry
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7
--
Jazz Pharmaceuticals Public Limited Company is a public limited liability company established in March 2005 under the laws of Ireland. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on the identification, development and commercialization of pharmaceutical products to meet huge medical needs.
Since its establishment in 2003, it has established a commercial and development organization, and the assembled products and product candidates currently include two products on sale, as well as product candidates that are in various stages of clinical development. It currently sells two products: Xyrem (sodium oxybate), the only product approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy due to drowsiness and excessive daytime sleepiness; and blue-release CR (fluvoxamine maleate) for the treatment of obsessive-compulsive disorder. The Company promotes sales of these products in the United States through its experienced professional sales force of sleep specialists, neurologists, pulmonologists and psychiatrists.
Earnings Call
Q1/2025
Estimate EPS4.66
Actual EPS1.68
Estimate Revenue983.75M
Actual Revenue897.84M
Jazz Pharmaceuticals Q1 2025: Navigating Key Contradictions in Xywav Supply, Epidiolex Strategy, and Rylaze Revenue
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-6.25
Actual EPS-8.25
Estimate Revenue1.05B
Actual Revenue1.05B
Jazz Pharmaceuticals' Q2 2025: Unpacking Contradictions in Xywav Growth, Zepzelca Challenges, and M&A Strategy
Aug 06,2025 05:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
JAZZ has released its 2025 Q3 earnings. EPS was reported at 8.13, versus the expected 5.85, beating expectations. The chart below visualizes how JAZZ has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
JAZZ has released its 2025 Q3 earnings report, with revenue of 1.13B, reflecting a YoY change of 6.74%, and net profit of 251.41M, showing a YoY change of 16.91%. The Sankey diagram below clearly presents JAZZ's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
